Clin Psychopharmacol Neurosci. 2018 Aug 31; 16 (3): 276-281. Doi: 10.9758 / cpn.2018.16.3.276.
Paik SH1, Choi MR1, Kwak SM1, Bang SH1, Kim DJ1.
inahaneloang
Morero:
Phetoho ea boteng ba glutamatergic neurotransication le dopaminergic dysfunction e bile le tšusumetso ho bobeli ba ho qala le polelo ea boitšoaro bo amanang le bokhoba. Boithuto bona ba lifofane bo ne bo reretsoe ho fuputsa maemo a serum a glutamate le dopamine ho batho ba baholo ba nang le bothata ba lipapali tsa marang-rang (IGD).
Mekhoa:
Re lekantsitse maemo a serum ea glutamate le dopamine ho barupeluoa ba banna ba nang le IGD (n = 26) le litekanyetso tsa lilemo tse tsamaeang le phepo e nepahetseng (n = 25). Lipuisano tsa bongaka li ile tsa etsoa ho khetholla IGD le ho khaola li-comorbidities tsa kelello. Maemo a serum a glutamate le dopamine a ile a hlahlojoa ke li-enzyme immunoassays a sebelisa ELISA Kits.
Results:
Mefuta ea serum ea glutamate e ne e le tlase ho IGD ho feta taolo (IGD: 24.184 ± 12.303 μg / ml; taolo: 33.676 ± 12.413 μg / ml; t = 2.742, p= 0.008), ha maemo a dopamine a ne a sa fapana pakeng tsa. Boemo ba serum glutamate le dopamine ha boa ka ba lumellana le lihora tsa papali le ho pepesetsoa papali sehlopheng sa IGD. Empa maemo a serum glutamate a ne a amana hantle le maemo a dopamine (r = 0.360, p= 0.013).
fihlela qeto ena:
Liphetho tsa rona li bontša hore li-neurotransication tse fetotsoeng li ka kenya letsoho ho pathophysiology ea IGD.
LITLHAKISO: Dopamine; Glutamates; Bothata ba lipapali tsa inthanete; Serum.
PMID: 30121977
DOI: 10.9758 / cpn.2018.16.3.276
Mahala ka botlalo
;